Trial Profile
A Multi-center, Phase 2 Study Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3A-APC in Combination With tPA, Mechanical Thrombectomy or Both in Moderate to Severe Acute Ischemic Stroke
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs 3K3A APC (Primary)
- Indications Stroke
- Focus Adverse reactions
- Acronyms RHAPSODY
- Sponsors ZZ Biotech
- 21 Feb 2020 Results Characterizing Cerebral Morphometry Changes and Effects of 3K3A-APC in Ischemic Stroke, presented at the International Stroke Conference 2020
- 21 Feb 2020 Results of hemorrhagic transformation when co-administered with conventional recanalization in acute ischemic stroke patients were presented at the International Stroke Conference 2020
- 18 Nov 2018 Results determining the maximally tolerated dose (MTD), published in the Annals of Neurology.